Test Code ASPAG Aspergillus (Galactomannan) Antigen, Serum
Reporting Name
Aspergillus Ag, SUseful For
Aiding in the diagnosis of invasive aspergillosis
Assessing response to therapy
Performing Laboratory
Mayo Clinic Laboratories in RochesterSpecimen Type
Serum SSTOrdering Guidance
For bronchoalveolar lavage specimens, order ASPBA / Aspergillus Antigen, Bronchoalveolar Lavage.
Specimen Required
Container/Tube: Serum gel (red-top tubes are not acceptable)
Specimen Volume: 1.5 mL
Collection Instructions:
1. Avoid exposure of specimen to atmosphere to prevent sample contamination from environment.
2. Centrifuge and send specimen in original tube. Do not aliquot or open tube.
Specimen Minimum Volume
1 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum SST | Refrigerated (preferred) | 14 days | SERUM GEL TUBE |
Frozen | 14 days | SERUM GEL TUBE |
Reference Values
<0.5 index
Reference values apply to all ages.
Day(s) Performed
Monday through Friday, Sunday
Test Classification
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.CPT Code Information
87305
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
ASPAG | Aspergillus Ag, S | 44357-2 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
84356 | Aspergillus Ag, S | 44357-2 |
Interpretation
A positive result supports a diagnosis of invasive aspergillosis (IA). Positive results should be considered in conjunction with other diagnostic procedures, such as microbiologic culture, histological examination of biopsy specimens, and radiographic evidence. See Cautions.
A negative result does not rule out the diagnosis of IA. Repeat testing is recommended if the result is negative but IA is clinically suspected. Patients at risk of IA should have a baseline serum tested and should be monitored twice a week for increasing galactomannan antigen levels.
Galactomannan antigen levels may be useful in the assessment of therapeutic response. Antigen levels decline in response to antimicrobial therapy.
Clinical Reference
1. Maertens J, Verhaegen J, Lagrou K, Boogaerts M: Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective evaluation. Blood. 2001 March 15;97(6):1604-1610
2. Pinel C, Fricker-Hidalgo H, Lebeau B, et al: Detection of circulating Aspergillus fumigatus galactomannan: value and limits of the Platelia test for diagnosing invasive aspergillosis. J Clin Microbiol. 2003 May;41(5):2184-2186
3. Swanink CM, Meis JF, Rijs AJ, Donnelly JP, Verweij PE: Specificity of a sandwich enzyme-linked immunosorbent assay for detecting Aspergillus galactomannan. J Clin Microbiol. 1997 Jan;35(1):257-260
4. Ansorg R, van den Boom R, Rath PM: Detection of Aspergillus galactomannan antigen in foods and antibiotics. Mycoses. 1997 Dec;40(9-10):353-357
5. Connolly P, Durkin M, Wheat LJ, et al: Rapid diagnosis of systemic and invasive mycoses. Clinical Microbiology Newsletter. 2007 Jan;29(1):1-5
Report Available
1 to 4 daysMethod Name
Enzyme Immunoassay (EIA)